<DOC>
	<DOCNO>NCT03028142</DOCNO>
	<brief_summary>This phase II , randomise , double blind , placebo control , complete block , three way crossover study investigate treatment nebulised RPL554 tiotropium together patient moderate severe chronic obstructive pulmonary disease ( COPD ) . The purpose study assess bronchodilator effect ( open airway ) RPL554 use combination long act anti-muscarinic receptor antagonist ( tiotropium ) whilst dose RPL554 steady state blood level . It plan randomise 30 patient 24 evaluable patient one study centre . In treatment period , patient receive open label dose tiotropium dry power inhaler ( DPI ) follow immediately double blind dose either RPL554 6mg , 1.5mg placebo ( depend treatment sequence ) nebuliser morning Day 1 , Day 2 Day 3 . The dose RPL554 placebo repeat evening Day 1 Day 2; even dose Day 3 .</brief_summary>
	<brief_title>The Effects RPL554 Addition Tiotropium COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Sign inform consent document indicate understand purpose procedure require study willing participate study . 2 . Male female age 40 75 year inclusive , time informed consent . 3 . If male : must agree meet follow first dose 1 month last dose study treatment : Not donate sperm Either : sexually abstinent accordance patient 's usual preferred lifestyle ( agree abide contraception requirement circumstance change ) Or : use condom sexual partner . If partner childbearing potential condom must use spermicide second highly effective form contraception must also use 4 . If female : either : 1 . Of nonchildbearing potential define : Either : postmenopausal ( spontaneously amenorrhoeic least 1 year appropriate clinical profile [ e.g . age appropriate , history vasomotor symptom ] Or : permanently sterilise e.g . tubal occlusion , hysterectomy , bilateral oophorectomy , bilateral salpingectomy 2 . Of childbearing potential agree use highly effective method contraception ( defined Section 8.4 ) completion end study visit . 5 . Have 12lead ECG record screen randomisation ( predose Treatment Period 1 ) show follow : Heart rate 45 90 beat per minute ( bpm ) QT interval correct heart rate use Fridericia 's formula ( QTcF ) ≤450 msec male ≤470 ms female QRS interval ≤120 msec No clinically significant abnormality ( judged Investigator ) include morphology ( e.g . leave bundle branch block , atrioventricular nodal dysfunction , ST segment abnormality ) 6 . Have screen Holter report minimum 18 hour record able evaluate rhythm analysis show abnormality indicate significant impairment patient safety may significantly impair interpretation opinion Investigator include : Significant arrhythmia include atrial flutter , atrial fibrillation , ventricular tachycardia Any symptomatic arrhythmia ( except isolate extra systole ) Any sustained second third degree heart block 7 . Capable comply study restriction procedure include ability use study nebuliser HandiHaler® DPI correctly . 8 . Body mass index ( BMI ) 18 33 kg/m2 ( inclusive ) minimum weight 45 kg . 9 . COPD diagnosis : Patients diagnosis COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) guideline ( Celli MacNee , 2004 ) symptom compatible COPD least 1 year prior screen . 10 . Postbronchodilator ( four puff salbutamol ) spirometry screening : Postbronchodilator FEV1/forced vital capacity ( FVC ) ratio ≤0.70 Postbronchodilator FEV1 ≥40 % ≤80 % predict normal Demonstrates ≥150 mL increase prebronchodilator FEV1 11 . Clinically stable COPD 4 week prior screen randomisation ( predose Treatment Period 1 ) . 12 . A chest Xray ( postanterior ) screening , 12 month prior screen show abnormality , clinically significant unrelated COPD . 13 . Meet concomitant medication restriction expect rest study . 14 . Smoking history ≥10 pack year . 15 . Capable withdraw long acting bronchodilator duration study , short act bronchodilator 8 hour prior spirometry . 1 . A history lifethreatening COPD exacerbation include Intensive Care Unit admission and/or require intubation . 2 . COPD exacerbation require oral steroid , low respiratory tract infection require antibiotic , 3 month prior screen randomisation ( predose Treatment Period 1 ) . 3 . A history one hospitalisation COPD 12 month prior screen randomisation ( predose Treatment Period 1 ) . 4 . Lactation ( female patient ) . 5 . Positive urine serum pregnancy test screening , positive urine pregnancy test prior randomisation ( female patient childbearing potential ) . 6 . Prior exposure RPL554 know hypersensitivity RPL554 component . 7 . Intolerance hypersensitivity tiotropium . 8 . Evidence cor pulmonale . 9 . Other respiratory disorder : Patients current diagnosis asthma , active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , interstitial lung disease , sleep apnoea , know alpha1 antitrypsin deficiency active pulmonary disease . 10 . Previous lung resection lung reduction surgery . 11 . Use oral COPD medication ( e.g . oral steroid , theophylline romifulast ) 3 month prior screen randomisation ( predose Treatment Period 1 ) . 12 . History , reason believe , patient drug alcohol abuse within past 3 year . 13 . Inability perform technically acceptable spirometry whole body plethysmography ( screen randomisation [ pre dose Treatment Period 1 ] ) 14 . Received experimental drug within 30 day five half life , whichever longer . 15 . Patients history chronic uncontrolled disease include , limited , endocrine , active hyperthyroidism , neurological , hepatic , gastrointestinal , renal , haematological , urological , immunological , ophthalmic disease Investigator believe clinically significant . 16 . Documented cardiovascular disease : arrhythmia , angina , recent suspect myocardial infarction , congestive heart failure , history unstable , uncontrolled hypertension , diagnose hypertension 3 month prior screen randomisation . 17 . Concurrent use noncardioselective oral betablockers . 18 . Has major surgery , ( require general anaesthesia ) 6 week prior screen randomisation ( predose Treatment Period 1 ) , fully recover surgery , plan surgery end study . 19 . A disclosed history one know Investigator , significant non compliance previous investigational study prescribe medication . 20 . Requires oxygen therapy , even occasional basis . 21 . Clinically significant prostatic hyperplasia ( judged Investigator ) bladderneck obstruction narrowangle glaucoma . 22 . Any reason Investigator considers make patient unsuitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>